Survival
Advancing Rare Cancer Therapeutics: Osimertinib-Loaded Inhaled PLGA Nanoparticles for Mesothelioma Treatment
AAPS PharmSciTech 2026 March 4 [Link] Mural Quadros, Naveen Rajana, Vivek Gupta Abstract Despite advances in mesothelioma treatment, malignant pleural mesothelioma (MPM) continues to present a poor prognosis due to its aggressive progression and resistance to conventional therapies. Current treatment modalities, including surgery, chemotherapy, radiation, and immunotherapy, offer limited efficacy, with a five-year survival rate…
Read MoreEffects of Autophagy Inhibition by SAR405, a Selective VPS34 Inhibitor, on Pleural Mesothelioma Cells
Thoracic Cancer 2026 March [Link] Yoshiki Kuwabara, Kosuke Sakai, Kota Shiraishi, Itsuka Matsumoto, Shigeru Ishii, Shin Yokosuka, Masatoshi Abe, Tomoyuki Takahashi, Yuichiro Kawano, Hiroaki Nishimura, Maiko Toda-Sasaki, Yumiko Kobayashi-Ogawa, Satoshi Kikuchi 1, Yusuke Hirata 1, Hiroyuki Kyoyama, Gaku Moriyama, Nobuyuki Koyama, Kazutsugu Uematsu Abstract Background: Pleural mesothelioma is a highly aggressive malignancy with a poor…
Read MoreClinical Importance of Molecular Biomarkers in Pleural Mesothelioma
Cancers 2026 February 19 [Link] Logan Roof, Kenna Koehler, Claire Verschraegen Abstract Pleural mesothelioma (PM) is a rare malignancy with opportunities for improvement in current treatment paradigms despite recent advances in systemic therapy. While histology remains the most clinically relevant prognostic indicator, the expanding use of immunotherapy and ongoing clinical trials involving targeted therapies have…
Read MoreFive-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
Journal of Clinical Oncology 2026 March 20 [Link] Arnaud Scherpereel, Paul Baas, Anna K Nowak, Anne S Tsao, Nobukazu Fujimoto, Solange Peters, Aaron S Mansfield, Sanjay Popat, Yolanda Bautista Aragon, Toby Talbot, Francesco Grossi, Dariusz Kowalski, Muhammet A Kaplan, Andrés Felipe Cardona, Raheela Soomro, Nan Hu, Adam Lee, Virginia Ip, Yu-Han Hung, Gérard Zalcman Abstract…
Read MoreMesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models
Scientific Reports 2026 February 25 [Link] M Lizeth Orozco Morales, Sally M Lansley, Wee Loong Chin, Caitlin M Tilsed, Nicola Principe, Connull Leslie, Breana J Vitali, Francois X Rwandamuriye, Emma de Jong, Joel Kidman, Rachael M Zemek, Catherine A Rinaldi 6, Timo Lassmann 3, Anthony Bosco 7, Y C Gary Lee, Richard A Lake, Jonathan…
Read MoreMoving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma
Journal of Thoracic Oncology 2026 February 20 [Link] Gabrielle Drevet, Lipika Kalson, Laurane Mangé, Francoise Galateau-Salle, Arnaud Scherpereel, Lara Chalabreysse, Julien Mazières, Luka Brcic, Nicolas Alcala, Jean-Michel Maury, Lynnette Fernandez-Cuesta, Matthieu Foll Abstract Despite recent advances in the treatment of pleural mesothelioma, it remains a challenging and heterogeneous disease, with limited options for patients. Survival…
Read MoreAnalysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study
Frontiers in Oncology 2026 February 3 [Link] Zhi-Ran Yang, Xin-Li Liang, Xin-Bao Li, Xin-Jing Zhang, He-Liang Wu, Yan-Dong Su, Yan Li, Song-Lin An Abstract Objective: To investigate the efficacy and safety of pemetrexed/platinum-based chemotherapy combined with or without bevacizumab after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of patients with malignant…
Read MoreRadiofrequency Ablation for Recurrent Pleural Mesothelioma
Cancers 2026 January 26 [Link] Hiroshi Kodama, Kozo Kuribayashi, Haruyuki Takaki, Kosuke Matsuda, Takashi Shinkai, Reona Wada, Atsushi Ogasawara, Masaki Hashimoto, Daichi Fujimoto, Toshiyuki Minami, Soichiro Funaki, Takashi Kijima, Koichiro Yamakado Abstract Background/Objectives: Pleural mesothelioma (PM) frequently recurs despite multimodal therapy. Here, we aimed to retrospectively evaluate the safety and potential clinical benefit of radiofrequency…
Read MoreValidation of chemoresistance phenotypes in pleural mesothelioma across 2D, 3D, and in vivo models
Scientific Reports 2026 February 11 [Link] Huaikai Shi, Sakthi Priya Selvamani, Richard Zelei, Ling Zhuang, Dongwei Wang, Ben Johnson, Vivek Dharwal, Duo Xu, Yiwei Wang, Tristan Rutland, Sonja Klebe, Steven Kao, Anthony Linton, Elham Hosseini-Beheshti, Yuen Yee Cheng Abstract Pleural mesothelioma (PM) is a highly aggressive cancer with limited treatment efficacy and poor prognosis. Conventional…
Read MoreFeasibility of multimodality treatment, including pleurectomy decortication, in carefully selected patients with sarcomatoid mesothelioma
Translational Lung Cancer Research 202t6 January 31 [Link] Moshe Lapidot, Emanuele Mazzola, Raphael Bueno Abstract Background: Pleural mesothelioma (PM) represents an uncommon and exceptionally lethal malignancy. The sarcomatoid subtype constitutes the rarest histological variant, traditionally linked to the worst prognosis, while the advantages of operative intervention remain inadequately established. In this study, we present findings…
Read More
Skip to content